{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:53:47Z","timestamp":1774122827722,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C9317\/A1990"],"award-info":[{"award-number":["C9317\/A1990"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-2586-7","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:31:11Z","timestamp":1522801871000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["SPIRE \u2013 combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib\/randomised IIa open label clinical trial"],"prefix":"10.1186","volume":"19","author":[{"given":"Simon","family":"Crabb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah J.","family":"Danson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W. F.","family":"Catto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"McDowell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James N.","family":"Lowder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Caddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Dunkley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Rajaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hathorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihalis","family":"Kalevras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Huddart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gareth","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"key":"2586_CR1","unstructured":"Cancer Research UK. http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/bladder-cancer . Accessed 26 Mar 2018."},{"key":"2586_CR2","first-page":"859","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, White RW, Sarosdy MF, Wood DP, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced. Bladder Cancer. 2003;349:859\u201366.","journal-title":"Bladder Cancer"},{"key":"2586_CR3","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","volume":"29","author":"G Griffiths","year":"2011","unstructured":"International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder; Norwegian Bladder Cancer Study Group, Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171\u20137.","journal-title":"J Clin Oncol"},{"key":"2586_CR4","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H Von Der Maase","year":"2000","unstructured":"Von Der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a Large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068\u201377.","journal-title":"J Clin Oncol"},{"key":"2586_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2174\/1574885511005010017","volume":"5","author":"SJ Crabb","year":"2010","unstructured":"Crabb SJ, Wheater M. Advances in chemotherapy and targeted systemic therapies for urothelial cancer. Curr Drug Ther. 2010;5:17\u201328.","journal-title":"Curr Drug Ther"},{"key":"2586_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","volume":"48","author":"CL Vale","year":"2005","unstructured":"Vale CL. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:202\u20136.","journal-title":"Eur Urol"},{"key":"2586_CR7","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H Von Der Maase","year":"2005","unstructured":"Von Der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602\u20138.","journal-title":"J Clin Oncol"},{"key":"2586_CR8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2016","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2016;376:1015\u201326.","journal-title":"N Engl J Med"},{"key":"2586_CR9","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1158\/1078-0432.CCR-13-2805","volume":"20","author":"RN Drayton","year":"2014","unstructured":"Drayton RN, Dudziec E, Peter S, Hartmann A, Bryant HE, Catto JW. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine\/glutamate exchanger SLC7A11. Clin Cancer Res. 2014;20:1990\u20132000.","journal-title":"Clin Cancer Res"},{"key":"2586_CR10","doi-asserted-by":"publisher","first-page":"e32750","DOI":"10.1371\/journal.pone.0032750","volume":"7","author":"E Dudziec","year":"2012","unstructured":"Dudziec E, Gogl-Doring A, Cookson V, Chen W, Catto JWR. Integrated epigenome profiling of repressive histone modifications DNA methylation and gene expression in normal and malignant urothelial cells. PLoS One. 2012;7:e32750.","journal-title":"PLoS One"},{"key":"2586_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/jnci\/95.5.399","volume":"95","author":"JC Cheng","year":"2003","unstructured":"Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst. 2003;95:399\u2013409.","journal-title":"J Natl Cancer Inst"},{"key":"2586_CR12","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/sj.bjc.6603482","volume":"95","author":"F Christoph","year":"2006","unstructured":"Christoph F, Kempkensteffen C, Weikert S, K\u00f6llermann J, Krause H, Miller K, et al. Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br J Cancer. 2006;95:1701\u20137.","journal-title":"Br J Cancer"},{"key":"2586_CR13","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.urology.2007.11.029","volume":"71","author":"D Shang","year":"2008","unstructured":"Shang D, Liu Y, Matsui Y, Ito N, Nishiyama H, Kamoto T, et al. Demethylating agent 5-aza-2\u2032-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to cisplatin. Urology. 2008;71:1220\u20135.","journal-title":"Urology"},{"key":"2586_CR14","unstructured":"Ramachandran K, Gordian E, Singal R. 5-Azacytidine reverses drug resistance in bladder cancer cells. Anticancer Res. 2011;31:3757\u201366."},{"key":"2586_CR15","doi-asserted-by":"crossref","unstructured":"Huihui Zhang, Fan Qi, Youhan Cao, Xiongbing Zu, Minfeng Chen, Zhuo Li and LQ. 5-Aza-2\u2019Deoxycytidine Enhances Maspin Expression and Inhibits Proliferation, Migration, and Invasion of the Bladder Cancer T24 Cell Line. Cancer Biother Radiopharm. 2013;28:343\u201350.","DOI":"10.1089\/cbr.2012.1303"},{"key":"2586_CR16","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1158\/0008-5472.CAN-09-3427","volume":"70","author":"X Chang","year":"2010","unstructured":"Chang X, Monitto CL, Demokan S, Kim MS, Chang SS, Zhong X, et al. Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res. 2010;70:2870\u20139.","journal-title":"Cancer Res"},{"key":"2586_CR17","first-page":"727","volume":"39","author":"Y Tada","year":"2011","unstructured":"Tada Y, Yokomizo A, Shiota M, Tsunoda T, Plass C, Naito S. Aberrant DNA methylation of T-cell leukemia, homeobox 3 modulates cisplatin sensitivity in bladder cancer. Int J Oncol. 2011;39:727\u201333.","journal-title":"Int J Oncol"},{"key":"2586_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4161\/15384047.2014.986967","volume":"16","author":"BK Samulitis","year":"2015","unstructured":"Samulitis BK, Pond KW, Pond E, Cress AE, Patel H, Wisner L, et al. Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther. 2015;16:43\u201351.","journal-title":"Cancer Biol Ther"},{"key":"2586_CR19","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.3892\/ijo.2014.2792","volume":"46","author":"M F\u00fcller","year":"2015","unstructured":"F\u00fcller M, Klein M, Schmidt E, Rohde C, G\u00f6llner S, Schulze I, et al. 5-azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation. Int J Oncol. 2015;46:1192\u2013204.","journal-title":"Int J Oncol"},{"key":"2586_CR20","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3892\/ijmm.2012.1138","volume":"30","author":"SG Gray","year":"2012","unstructured":"Gray SG, Baird AM, O\u2019Kelly F, Nikolaidis G, Almgren M, Meunier A, et al. Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor. Int J Mol Med. 2012;30:1505\u201311.","journal-title":"Int J Mol Med"},{"key":"2586_CR21","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.exphem.2012.06.001","volume":"40","author":"BC Valdez","year":"2012","unstructured":"Valdez BC, Nieto Y, Murray D, Li Y, Wang G, Champlin RE, et al. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Exp Hematol. 2012;40:800\u201310.","journal-title":"Exp Hematol"},{"key":"2586_CR22","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1470-2045(15)00038-8","volume":"16","author":"J-PJ Issa","year":"2015","unstructured":"Issa J-PJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O\u2019Connell C, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015;16:1099\u2013110.","journal-title":"Lancet Oncol"},{"key":"2586_CR23","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(17)30576-4","volume":"18","author":"HM Kantarjian","year":"2017","unstructured":"Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O\u2019Connell CL, Tibes R, et al. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1\/2 trial. Lancet Oncol. 2017;18:1317\u201326.","journal-title":"Lancet Oncol"},{"key":"2586_CR24","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-11-3909","volume":"72","author":"D Matei","year":"2012","unstructured":"Matei D, Fang F, Changyu S, Schilder J, Arnold A, Zeng Y, et al. Epigenetic resensitzation to platinum in ovarian cancer. Cancer Res. 2012;72:2197\u2013205.","journal-title":"Cancer Res"},{"key":"2586_CR25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.4161\/epi.4.3.8694","volume":"4","author":"A Aparicio","year":"2009","unstructured":"Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, et al. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics. 2009;4:176\u201384.","journal-title":"Epigenetics"},{"key":"2586_CR26","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1200\/JCO.2007.10.8688","volume":"25","author":"K Appleton","year":"2007","unstructured":"Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 2007;25:4603\u20139.","journal-title":"J Clin Oncol"},{"key":"2586_CR27","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.urolonc.2009.09.015","volume":"29","author":"G Sonpavde","year":"2011","unstructured":"Sonpavde G, Aparicio AM, Zhan F, North B, DeLaune R, Garbo LE, et al. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemona\u00efve castration-resistant prostate cancer. Urol Oncol Semin Orig Investig. 2011;29:682\u20139.","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"2","key":"2586_CR28","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.2007.12.7712","volume":"26","author":"JM Skolnik","year":"2008","unstructured":"Skolnik JM, Barrett JS, Jayaraman B, Patel D, Adamson PC. Shortening the timeline of pediatric phase I trials: the rolling six design. J Clin Oncol. 2008;26(2):190\u20135.","journal-title":"J Clin Oncol"},{"key":"2586_CR29","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1128\/AAC.06161-11","volume":"56","author":"CL Clouser","year":"2012","unstructured":"Clouser CL, Holtz CM, Mullett M, Crankshaw DL, Briggs JE, O\u2019Sullivan MG, et al. Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1. Antimicrob Agents Chemother. 2012;56:1942\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"2586_CR30","unstructured":"University Hospital Southampton website. http:\/\/www.uhs.nhs.uk\/Research\/Research.aspx . Accessed 18 Jan 2018."},{"key":"2586_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, et al. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200\u20137.","journal-title":"Ann Intern Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2586-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-2586-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2586-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T22:08:53Z","timestamp":1571004533000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-2586-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2586"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-2586-7","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]},"assertion":[{"value":"1 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial received favourable ethical opinion from the North West-Haydock Research Ethics Committee (15\/NW\/0936) and has Health Research Authority (HRA) approval (IRAS 183621). All participants provide written informed consent to participate and are free to withdraw at any time.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SC has received research funding from AstraZeneca, Clovis Oncology and Plexxikon and has undertaken advisory work or received speaker fees from Janssen, Roche and Astellas. JWFC has received funding from Roche for a medical lecture. JL is an employee of Astex Pharmaceuticals, who are supporting the trial through the Cancer Research UK Experimental Cancer Medicine Centres (ECMC) drug combination alliance (but where responsibility for the final protocol lies with SC, GG and the academic sponsor). All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"216"}}